Better Buy: GW Pharmaceuticals vs. Amarin

This biotech has a product on the market with tremendous growth potential. Investors' interest in its stock has skyrocketed over the last couple of years. And with a market cap of only around $5 billion, the company could have a lot more room to run. 

Which biotech am I referring to: GW Pharmaceuticals (NASDAQ: GWPH) or Amarin (NASDAQ: AMRN)? Both match the description perfectly.

GW has been the bigger winner so far in 2019. Amarin has delivered much higher gains over the last 12 months. So which biotech stock is the better pick for investors now?

Continue reading

Source Fool.com